Intellia Therapeutics Obtains $15,000,000 Series A Funding Round

  • Feed Type
  • Date
    11/19/2014
  • Company Name
    Intellia Therapeutics
  • Mailing Address
    130 Brookline Street Cambridge, MA 02139 USA
  • Company Description
    Intellia Therapeutic’s core mission is to lead the industry in therapeutic gene editing, utilizing the promise of the CRISPR/Cas9 technology. We are solely focused on the research and clinical development of gene editing therapies for patients with genetically-based diseases.
  • Website
    http://www.intelliatx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $15,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy